Kjeldsen S, Feldman RD, Lisheng L, Mourad JJ, Chiang CE, Zhang W, Wu Z, Li W, Williams B. Updated national and international hypertension guidelines: a review of current recommendations. Drugs. 2014;74(17):2033–51.
Whelton PK, Carey RM, Aronow WS, Casey DE, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertension. 2017;19(19):213–21.
Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global burden of hypertension: analysis of population-based studies from 89 Countries. J Hypertens. 2015. https://doi.org/10.1097/01.hjh.0000469726.59998.cc.
Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015;65(6):1372–407.
Mandal A. Study of prevalence of type 2 diabetes mellitus and hypertension in overweight and obese people. J Fam Med Prim Care. 2014;3(1):25.
Moore LL, Visioni AJ, Qureshi MM. Weight loss in overweight adults and the long-term risk of hypertension: the Framingham Study. ACC Curr J Rev. 2005;14(9):6–7.
Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet. 2014;383(9921):970–83.
Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, van Dam RM, Hu FB, Visscher TL, Menotti A, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 3,00,000 persons. Arch Intern Med. 2007;167(16):1720–8.
Ferland A, Eckel RH. Does sustained weight loss reverse the metabolic syndrome? Curr Hypertens Rep. 2011;13(6):456–64.
Somes GW, Kritchevsky SB, Shorr RI, Marco P, Applegate WB. Body mass index, weight change, and death in older adults: the systolic hypertension in the elderly program. Am J Epidemiol. 2002;2:132.
Yang G, Shu XO, Gao YT, Zhang X, Li H, Zheng W. Impacts of weight change on prehypertension in middle-aged and elderly women. Int J Obes. 2007;31(12):1818.
Cordero A, Bertomeu-Martínez V, Mazón P, Martín-Raymondi D, Palma JL, Anguita M, Lekuona IA, Galve E, González-Juanatey JR. Short-term metabolic changes achieved by weight loss in hypertensive patients. Int J Cardiol. 2011;153(3):286–90.
Jiang M, Lu C, Zhang C, Yang J, Tan Y, Lu A, Chan K. Syndrome differentiation in modern research of traditional Chinese medicine. J Ethnopharmacol. 2012;140(3):634.
Wang J, Wang Q, Li L, Li Y, Zhang H, Zheng L, Yang L, Zheng Y, Yang Y, Peng G. Phlegm-dampness constitution: genomics, susceptibility, adjustment and treatment with traditional Chinese medicine. Am J Chin Med. 2013;41(2):253–62.
Wu QF, Wen MX, Lan DH. Effects of Banxia Baizhu Tianma Decoction on Insulin Resistance and Blood Lipid of Hypertension with Abundant Phlegm-dampness Syndrome. J Fujian Coll Tradit Chin Med. 2007; 17(2):8-10.
Wang Q, Gong H, Gao J. Study on Characteristics of Peripheral Blood Gene Expression Profile in the Obesity with Phlegm-Dampness Constitution. J Tradit Chin Med. 2006;47:851–8.
World Health Organization. Regional Office for the Western Pacific. (2007). WHO international standard terminologies on traditional medicine in the Western Pacific Region. Manila : WHO Regional Office for the Western Pacific. https://apps.who.int/iris/handle/10665/206952
Chu YG, Shi J, Hu YH, Wu HQ, Liu GJ, Hu CJ, Li YZ, Li Y, Chen ZJ, He Q. Serum proteomes of hypertension patients with abundant phlegm-dampness. J Integr Med. 2009;7(7):629–35.
Guo X, Zhang G. Health intervention for hypertension patients with phlegm-dampness syndrome. World J Integr Tradit West Med. 2016;11(4):537–9.
Flaws B, Sionneau P. The treatment of modern western diseases with Chinese medicine. Torrance: Blue Poppy Press; 2004.
Delles C, Neisius U, Carty DM. Proteomics in hypertension and other cardiovascular diseases. Ann Med. 2012;44(Suppl 1):S55-64.
Fuchs FD, de Mello RB, Fuchs SC. Preventing the progression of prehypertension to hypertension :role of antihypertensives. Curr Hypertens Rep. 2014. https://doi.org/10.1007/s11906-014-0505-1.
Levy D, Larson MG. The progression from hypertension to congestive heart failure. JAMA. 1996. https://doi.org/10.1001/jama.1996.03530440037034.
De Marco M, De Simone G, Roman MJ, Chinali M, Lee ET, Russell M, Howard BV, Devereux RB. Cardiovascular and metabolic predictors of progression of prehypertension into hypertension: the Strong Heart Study. Hypertension. 2009;54(5):974.
Stewart PA, Li J, Fisher KJ, Dhungana S, Stewart D, Sumner S, Gardner E, Poirier J, Rudin CM, Welsh EA. Abstract 3752: Integrating proteomics and metabolomics characterizes active pathways and potential drug targets in small cell lung cancer. Can Res. 2015;75(15 Supplement):3752.
Cai Z, Zhao JS, Li JJ, Peng DN, Wang XY, Chen TL, Qiu YP, Chen PP, Li WJ, Xu LY. A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol Cell Proteomics. 2010;9(12):2617.
China Association of Chinese Medicine. Classification and determination of Constitution in TCM. China Traditional Chinese Medicine Publishing House Beijing, 2009.
Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014. https://doi.org/10.4158/EP14280.PS.
James PA, Oparil S, Carter BL. evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014. https://doi.org/10.1001/jama.2013.284427.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Redón J, Böhm M, Christiaens T, Cifkova R. 2013 ESH/ESC practice guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2013;16(3):135.
Yong T, Xinru L, Ke Z, Xiaojuan H, Cheng L, Bing H, Xuyan N, Cheng X, Gang X, Zhaoxiang B. The potential biomarkers to identify the development of steatosis in hyperuricemia. PLoS ONE. 2016;11(2):e0149043.
Berdel WE, Hoff DDV, Unger C, Schick HD, Fink U, Reichert A, Rastetter EJ. Ether lipid derivatives: antineoplastic activity in vitro and the structure-activity relationship. Lipids. 1986. https://doi.org/10.1007/BF02536417.
Sekas G, Patton GM, Lincoln EC, Robins SJ. Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat. J Lab Clin Med. 1985;105(2):190–4.
Chapman MJ, Sposito AC. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Pharmacol Ther. 2008;117(3):354–73.
Floegel A, Drogan D, Weikert C, Pischon T, Dietrich S. Identification of serum metabolites associated with incident hypertension in the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. Hypertension. 2016. https://doi.org/10.1161/HYPERTENSIONAHA.116.07292.
Kulkarni H, Meikle PJ, Mamtani M, Weir JM. Plasma lipidomic profile signature of hypertension in Mexican American families: specific role of diacylglycerols. Hypertension. 2013. https://doi.org/10.1161/HYPERTENSIONAHA.113.01396.
Li L, Yang J, Lu CF. A study on the correlation of erythrocyte membrane phospholipids with lipid peroxidation and blood rheology in patients with essential hypertension. Chin J Cardiol. 1995; 23(003):188-190.
Bienias K, Fiedorowicz A, Sadowska A, Prokopiuk S, Car H. Regulation of sphingomyelin metabolism. Pharmacol Rep. 2016;68:570–81.
Medeiros C, Frederico MJ, Luz GD, Pauli JR, Silva ASR, Pinho RA, Velloso LA, Ropelle ER, Souza CTD. Exercise training reduces insulin resistance and upregulates the mTOR/p70S6k pathway in cardiac muscle of diet-induced obesity rats. J Cell Physiol. 2011;226(3):666–74.
Anaruma CP, Pereira RM, Rodrigues KCDC, Silva ASRD, Moura LPD. Rock protein as cardiac hypertrophy modulator in obesity and physical exercise. Life Sci. 2019;254:116955.
Jin L. Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. J Pharmacol Exp Ther. 2006;318(1):288–95.
Nunes KP, Rigsby CS, Webb RC. RhoA/Rho-kinase and vascular diseases: what is the link? Cell Mol Life Sci. 2010;67(22):3823.
Qian YS, Zhang Y, Zhou XO. Correlation study on serum adiponectiin abnormity with adiponectin gene polymorphisms in hypertensive patients of phlegm-dampness constitution. Chin J Integr Med. 2010;30(5):4.
Copenhaver M, Yu CY, Hoffman R. Complement components, C3 and C4, and the metabolic syndrome. Curr Diabetes Rev. 2018;15(1):44–8.
Engström G, Hedblad B, Berglund G, Janzon L, Lindgärde F. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J Hum Hypertens. 2007;21(4):276–82.
Nadar SK, Lip GYH. New insights into complement C3 and inflammation in hypertension. J Hum Hypertens. 2007;21(4):261–3.
Pérez E, Bourguet W, Gronemeyer H, Lera ARD. Modulation of RXR function through ligand design. Biochim Biophys Acta. 2012;1821(1):57–69.
Zhu J, Ning RB, Lin XY, Chai DJ, Xu CS, Xie H, Zeng JZ, Lin JX. Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway. Am J Hypertens. 2014. https://doi.org/10.1093/ajh/hpu017.
Dahlman I, Nilsson M, Jiao H, Hoffstedt J, Lindgren CM, Humphreys K, Kere J, Gustafsson JK, Arner P, Dahlman-Wright K. Liver X receptor gene polymorphisms and adipose tissue expression levels in obesity. Pharmacogenet Genomics. 2006;16(12):881–9.
Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes & Development. 2000;14(22):2831-2838.
Ren JG, Jie C, Talbot C. How PEDF prevents angiogenesis: a hypothesized pathway. Med Hypotheses. 2005;64(1):74–8.